Malignant pleural mesothelioma is a rare cancer that is typically associated with exposure to
asbestos. Patients with malignant pleural mesothelioma have poor outcomes with …

Purpose To provide evidence-based recommendations to practicing physicians and others
on the management of malignant pleural mesothelioma. Methods ASCO convened an …

Abstract Malignant Pleural Mesothelioma (MPM) remains a relevant public health issue, and
asbestos exposure is the most relevant risk factor. The incidence has considerably and …

Introduction Malignant pleural mesothelioma (MPM) has limited treatment options and a
poor outcome. Programmed death 1/programmed death ligand 1 (PD-L1) checkpoint …

Background Single-drug checkpoint inhibition has shown efficacy in patients with recurrent
malignant pleural mesothelioma. Here, we assessed the safety and efficacy of the …

Background Malignant pleural mesothelioma is a highly aggressive cancer with poor
prognosis and few treatment options following progression on platinum-containing …

Background Monoclonal antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) have
therapeutic activity in different tumour types. We aimed to investigate the efficacy, safety, and …

Background There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We
aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab …

Importance Patients with malignant mesothelioma whose disease has progressed after
platinum and pemetrexed treatment have limited options. Anti–programmed cell death 1 (PD …

Background CTLA4 blockade by tremelimumab 15 mg/kg every 90 days provided
preliminary evidence of activity in patients with pretreated malignant mesothelioma; …